GlassScriptPhysician profile
Trinh Tran
NPI 1417998626
$10,327.87
in general payments reported to CMS, 2019-2025
34 companies · $929 in 2025
The $929 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,886 · 2020: $1,709 · 2021: $1,830 · 2022: $1,758 · 2023: $1,052 · 2024: $1,163 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Education: $89.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.28 |
| Education | $89.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,453.02 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,375.77 | 2019-2025 | Enbrel, Uplizna, Evenity |
| Pfizer INC. | $1,350.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $843.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $683.72 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $492.97 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $445.10 | 2019-2023 | Tremfya |
| Horizon Therapeutics Plc | $441.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $397.18 | 2021-2025 | Saphnelo |
| Genentech USA, INC. | $363.97 | 2019-2025 | Actemra |
| Ucb, INC. | $324.49 | 2019-2024 | Cimzia |
| Lilly USA, LLC | $252.45 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $236.42 | 2019-2024 | Orencia |
| Genzyme Corporation | $229.70 | 2020-2025 | |
| Ani Pharmaceuticals, INC. | $201.73 | 2022-2023 | Purified Cortrophin Gel |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $168.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.21 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $133.01 | 2022-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $125.32 | 2019 | |
| Octapharma USA, INC. | $123.35 | 2023-2025 | Cutaquig, Octagam Immune Globulin (Human), Panzyga |
| Radius Health, INC. | $86.71 | 2019-2023 | Tymlos |
| Kyowa Kirin, INC. | $65.44 | 2023-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $56.87 | 2019-2024 | Strensiq |
| Celltrion USA INC. | $56.56 | 2023-2025 | Yuflyma, Vegzelma |
| Fresenius Kabi USA, LLC | $52.55 | 2024 | Idacio |
| Medexus Pharma, INC. | $41.16 | 2019 | |
| Merck Sharp & Dohme LLC | $29.61 | 2019 | |
| Celgene Corporation | $28.23 | 2019 | |
| Sobi, INC | $22.79 | 2024 | |
| Organon LLC | $21.97 | 2024 | |
| Gilead Sciences, INC. | $20.52 | 2020 | |
| Pacira Therapeutics, INC. | $19.67 | 2021 | |
| Antares Pharma, INC. | $13.61 | 2019 | |
| Hospira, INC. | $5.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trinh Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.